STOCK TITAN

ADMA Biologics, Inc. - $ADMA STOCK NEWS

Welcome to our dedicated page for ADMA Biologics news (Ticker: $ADMA), a resource for investors and traders seeking the latest updates and insights on ADMA Biologics stock.

ADMA Biologics, Inc. (Nasdaq: ADMA) is an end-to-end commercial biopharmaceutical company dedicated to the development, manufacturing, and commercialization of specialty plasma-derived biologics. The company's core focus is on treating immunocompromised patients at risk of infection, particularly those with primary immune deficiency diseases (PIDD) and other infectious diseases. ADMA's mission is to deliver critical therapeutics to niche patient populations through its robust product portfolio.

The company's lead product, RI-002, has successfully completed a Phase III clinical trial for treating PIDD, meeting its primary endpoint. The Biologics License Application (BLA) for RI-002 was accepted by the U.S. Food and Drug Administration (FDA) on September 18, 2015, marking a significant milestone for ADMA. Additionally, the company has received numerous U.S. patents, including U.S. Patent 9,107,906, further solidifying its innovative approach to plasma-derived therapies.

ADMA's commercial product lineup includes three FDA-approved plasma-derived biologics:

  • BIVIGAM® – Immune globulin intravenous for the treatment of primary humoral immunodeficiency (PI).
  • ASCENIV™ – Immune globulin intravenous (human – slra 10% liquid), indicated for PI treatment.
  • NABI-HB® – Hepatitis B immune globulin for enhanced immunity against the hepatitis B virus.

The company operates through two primary segments: ADMA BioManufacturing, which generates the majority of its revenue, and Plasma Collection Centers. ADMA BioCenters is responsible for collecting human plasma, a vital component for producing its therapeutic products. This network now includes multiple FDA-licensed collection centers across the United States.

ADMA has recently reported impressive financial milestones, including total revenues of $81.9 million for Q1 2024, a 44% year-over-year increase, and a Q1 2024 GAAP net income of $17.8 million, marking a significant turnaround. The company also reported first-time positive GAAP net income of $2.6 million in 3Q 2023, highlighting its profitable trajectory.

The company continues to innovate, leveraging technologies such as ADMAlytics™, an AI-driven platform aimed at optimizing production processes and improving operational efficiency. This platform is expected to provide substantial benefits across the company's supply chain and production operations.

ADMA's strategic growth initiatives include expanding its commercial product offerings, enhancing manufacturing yields, and advancing preclinical pipeline programs targeting S. pneumonia. The company has also secured a new $135 million credit facility to support its growth objectives further.

For more information about ADMA Biologics and its products, please visit the company's website at www.admabiologics.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.75%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.83%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.83%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.83%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.53%
Tags

FAQ

What are the primary products offered by ADMA Biologics?

ADMA Biologics offers three FDA-approved plasma-derived biologics: BIVIGAM® for primary humoral immunodeficiency, ASCENIV™ for primary immune deficiency disease, and NABI-HB® for enhanced immunity against hepatitis B.

What is ADMA Biologics' mission?

ADMA's mission is to manufacture, market, and develop specialty plasma-derived biologics targeted at niche patient populations for treating and preventing certain infectious diseases.

How has ADMA Biologics performed financially recently?

ADMA reported total revenues of $81.9 million for Q1 2024, a 44% increase year-over-year, and a Q1 2024 GAAP net income of $17.8 million. The company achieved first-time positive GAAP net income of $2.6 million in 3Q 2023.

What recent technological advancements has ADMA made?

ADMA has developed ADMAlytics™, an AI-driven platform designed to optimize production processes and enhance operational efficiency across its supply chain.

What is RI-002, and why is it significant for ADMA?

RI-002 is ADMA's lead product for treating primary immune deficiency disease (PIDD). It has successfully completed a Phase III clinical trial and received FDA acceptance for its Biologics License Application (BLA) in 2015.

What are ADMA Biologics' primary business segments?

ADMA operates through ADMA BioManufacturing, which generates most of its revenue, and Plasma Collection Centers responsible for collecting human plasma for therapeutic products.

How does ADMA Biologics plan to sustain its growth?

ADMA plans to sustain its growth by expanding its commercial product offerings, enhancing manufacturing yields, advancing preclinical pipeline programs, and leveraging its new $135 million credit facility.

What makes ASCENIV™ unique?

ASCENIV™ is an intravenous immune globulin that combines normal source plasma with respiratory syncytial virus (RSV) plasma, providing naturally occurring polyclonal antibodies to neutralize microbes and prevent infections.

Where can I find more information about ADMA Biologics?

More information about ADMA Biologics and its products can be found on the company's website at www.admabiologics.com.

What recent financial achievements has ADMA reported?

ADMA reported first-time positive GAAP net income of $2.6 million in 3Q 2023, Q1 2024 total revenues of $81.9 million, and a Q1 2024 GAAP net income of $17.8 million, indicating significant financial growth.

ADMA Biologics, Inc.

Nasdaq:ADMA

ADMA Rankings

ADMA Stock Data

2.46B
223.72M
2.59%
76.26%
3.2%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
RAMSEY